Vutrisiran (hereditary transthyretin-mediated amyloidosis with polyneuropathy (stage 1 or 2))

Subject:

• Active Substance: Vutrisiran
• Name: Amvuttra®
• Therapeutic area: Hereditary transthyretin-mediated amyloidosis
• Pharmaceutical company: Alnylam Germany GmbH

Time table:

• Start: 15.10.2022
• Final decision by G-BA: 06.04.2023

Final decision:

• Indication for a minor additional benefit